ASMB — Assembly Biosciences Share News
0.000.00%
Last trade - 00:00- $403.95m
- $83.59m
- $72.30m
Assembly climbs on quarterly revenue beat
Assembly Biosciences Q2 net loss narrows as revenue rises
Assembly Biosciences Q1 revenue falls, net loss widens
Assembly Biosciences 2025 net loss narrows
Assembly Biosciences rises as Gilead opts to license co's HSV therapies
Brief: Gilead Sciences Exercises Option To License Assembly Biosciences’ Helicase-Primase Inhibitor Programs For Recurrent Genital Herpes
Assembly Biosciences Q3 net loss narrows, raises $175 mln
Assembly Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Assembly Biosciences Q2 revenue rises from Gilead collaboration
Assembly Biosciences Inc expected to post a loss of $1.36 a share - Earnings Preview
Brief: Assembly Biosciences Appoints Alap Ghosh As CEO For India
Brief: Assembly Biosciences Doses First Participant In Phase 1B Portion Of Phase 1A/B Clinical Trial Of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor Abi-1179
Brief: Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Assembly Modulator in Chronic Hepatitis B
Brief: Assembly Biosciences Inc - Jeanette M. Bjorkquist Appointed Principal Financial Officer On June 5- SEC Filing
Assembly Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Assembly Biosciences Inc expected to post a loss of $1.60 a share - Earnings Preview
Brief: Assembly Biosciences Inc Files For Mixed Shelf Offering Of Up To $250 Million
Brief: Assembly Biosciences FY Net Income USD 40.177 Million
Advisory: Alert on executive appointment wrongly tagged to Assembly Biosciences withdrawn